Muscle-type nicotinic acetylcholine receptor (adult isoform) (nAChR)

The adult wild-type neuromuscular nicotinic acetylcholine receptor (nAChR) is a pentameric ligand-gated ion channel essential for signaling at the neuromuscular junction [1]. In adults, it typically consists of two alpha-1, one beta-1, one delta, and one epsilon subunit, a configuration that replaces the fetal gamma subunit to provide faster channel kinetics [2]. When acetylcholine binds to the two alpha subunits, the channel opens to allow the flow of cations, primarily sodium, into the muscle cell, resulting in depolarization and subsequent muscle contraction [3]. This receptor is the primary target for neuromuscular blocking agents (NMBAs) used during surgery, such as rocuronium and succinylcholine [4]. Pathologically, it is the target of autoantibodies in Myasthenia Gravis, leading to receptor degradation and impaired neuromuscular transmission [5]. Congenital mutations in the subunits, particularly the epsilon subunit, can lead to congenital myasthenic syndromes characterized by muscle weakness [2]. Therapeutic modulation of this receptor is critical for achieving muscle relaxation in clinical anesthesia and managing respiratory failure in intensive care [4]. Understanding its structure has also facilitated the development of reversal agents like sugammadex, which encapsulates certain NMBAs to restore receptor function [4]. Sources: [1] UniProt (P02708); [2] StatPearls (Neuromuscular Junction); [3] PubMed (PMID: 17007580); [4] PubChem (Succinylcholine); [5] NIH (Myasthenia Gravis).

Other names

Adult muscle-type nicotinic acetylcholine receptorNeuromuscular nicotinic acetylcholine receptorAlpha-1-beta-1-delta-epsilon nicotinic receptorCHRN receptorMuscle nAChR

Neuromuscular blocking agents act by either binding to and persistently activating the receptor, leading to a depolarizing block, or by competitively inhibiting the binding of acetylcholine to the alpha subunits, resulting in a non-depolarizing block [2][4].